The Markers That Matter. The Decision That Counts.
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Boston (U.S.) – Rotterdam (NL), 1 July 2014. SkylineDx today announced the
Response to Proteasome Inhibitors Can Be Predicted with Gene Expression Profiling Boston (U.S.A.)
Boston, MA, U.S., March 21, 2014 – SkylineDx announces the opening of a
Rotterdam, March 2014 – The European Myeloma Network (EMN) recommends the use
We would like to thank all our collaborators for a successful ASH
SkylineDx and leading institutes present three abstracts on multiple myeloma risk stratification